



SWITCHING FOCUS

Understanding the impact of unplanned psychotropic medication switches on patient outcomes

INVITATION

By participating in this program, HCPs will be able to:

- Understand the regulatory requirements for approval of innovator medicines and generics in Canada
- Explore potential areas of concern with the general use of generic psychotropic medications
- Demonstrate the potential consequences of switches when it comes to psychotropic medication

SCIENTIFIC COMMITTEE MEMBERS

Pierre Blier
MD, PhD
University of Ottawa

Jeffrey Habert
MD
University of Toronto

Howard Margolese
MD
McGill University

John Papastergiou
BPharm, RPh
University of Toronto

Adriana Wilson
MD
Dalhousie University

SPEAKER:

DATE:

TIME:

LOCATION / ADDRESS:

Please confirm your availability to attend by contacting

Name

By email at

or by telephone at

Linking Learning to Practice

Please note that this program is not accredited, however as a general practitioner, you have the possibility to earn credits for this learning program.

Additional information can be found on the cfpc website: http://www.cfpc.ca/Linking_Learning_exercises



This learning program is supported by Pfizer Canada Inc.